Also written as DAYBUE and DAYBUE STIX
Trofinetide is an IGF-1-derived tripeptide analog. It is filed in this library under brain & sleep, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA. It is also written as DAYBUE and DAYBUE STIX.
Regulatory status
Trofinetide has an FDA-approved product on the U.S. market, marketed as Daybue under application NDA217026.
The current label is held by Acadia Pharmaceuticals Inc.
From the FDA label
and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.Quoted from the FDA-approved prescribing information
The evidence
One source on Trofinetide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Trofinetide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides